This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ThromboGenics Business Update

LEUVEN, Belgium, May 16, 2013 /PRNewswire/ --

  • JETREA ®   gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 million
  • Phase IIa study evaluating JETREA ®   in wet AMD patients shows 24% VMA resolution rate for JETREA ® treated patients, versus 12% for sham injection. This positive trend and safety profile warrant further larger studies to confirm clinical benefits
  • Company Cash position: over €200 million

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines, today issued a business and financial update ending 30 April, 2013.

During 2013, ThromboGenics delivered a number of key corporate milestones, the most important of which was the launch of JETREA ® (ocriplasmin) in the US on 14 January via its own commercial organization. ThromboGenics' partner outside the US, Alcon, launched JETREA ® in the UK and Germany after its approval by the European Commission in March 2013. The EU approval and the launch of JETREA ® in the UK led to ThromboGenics receiving two equal milestones from Alcon amounting to a total of €90 million.

Following these launches, patients and physicians in the US and the EU now have access to the first pharmacological treatment for the sight-threatening condition known as symptomatic vitreomacular adhesion (VMA)/ vitreomacular traction (VMT) respectively. The launches of JETREA ® complete ThromboGenics' transformation into an integrated company with operations in R&D through to full-scale commercialization.  

ThromboGenics and Alcon are now focused on generating greater awareness of the drug and driving JETREA ® adoption and revenues in the US and Europe.  

Highlights (including post-period events):

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs